IL26 and chronic obstructive pulmonary disease: However, we still have a long way to go before we fully understand whether IL-26 possesses any clinical utility as a potent biomarker for diagnosis and monitoring and, more importantly, as a therapeutic target of one or more specific endotypes of COPD—particularly, those related with Th17-related neutrophilic airway inflammation.